Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Jun;118(4):893–900. doi: 10.1111/j.1476-5381.1996.tb15483.x

Effects of calcium antagonists on endothelin-1-induced myocardial ischaemia and oedema in the rat.

J G Filep 1, Y Skrobik 1, A Fournier 1, E Földes-Filep 1
PMCID: PMC1909521  PMID: 8799559

Abstract

1. The effects of the calcium channel blockers, verapamil and nifedipine on myocardial ischaemia and oedema evoked by endothelin-1 (ET-1) or IRL 1620, an ETB receptor-selective agonist were studied in anaesthetized and conscious rats. 2. Bolus injection of ET-1 (1 nmol kg-1, i.v.) or IRL 1620 (1 nmol kg-1, i.v.) to conscious chronically catheterized rats evoked a transient depressor response followed by a prolonged pressor effect. Corresponding to changes in blood pressure, a transient tachycardia and a sustained bradycardia were observed. Pretreatment of the animals with verapamil (1 mg kg-1, i.v.) or nifedipine (200 micrograms kg-1, i.v.) produced on average 5 mmHg decrease in mean arterial blood pressure. Both verapamil and nifedipine inhibited by 63 and 44% the pressor actions of ET-1 or IRL 1620 (1 nmol kg-1), respectively, and the accompanying bradycardia. Both verapamil and nifedipine potentiated the magnitude of the depressor action of ET-1 and IRL 1620 without affecting the accompanying tachycardia. Decreasing mean arterial blood pressure with hydralazine (0.2 - 0.3 micromol kg-1, i.v.) to levels comparable to those observed after verapamil or nifedipine had no significant effects on the haemodynamic responses to ET-1 or IRL-1620. 3. Intravenous bolus injection of ET-1 or IRL 1620 (0.1-2 nmol kg-1) into anaesthetized rats produced dose-dependent ST segment elevation of the electrocardiogram without causing arrhythmias. ST segment elevation developed within 30-50s and persisted for at least 10-20 min following injection of the peptides. 4. Pretreatment of the animals with verapamil (1 mg kg-1, i.v.) or nifedipine (200 micrograms kg-1, i.v.) inhibited on average by 79 and 76% the ST segment elevation elicited by ET-1 (1 nmol kg-1), respectively. Verapamil and nifedipine also attenuated IRL 1620 (1 nmol kg-1)-induced ST segment elevation on average by 71 and 74%, respectively. In contrast, no significant inhibition was observed with hydralazine (0.2-0.3 mumol kg-1). 5. Both ET-1 and, to a lesser extent, IRL 1620 (0.1-2 nmol kg-1) evoked albumin accumulation in cardiac tissues in a dose-dependent fashion as measured by the local extravascular accumulation of Evans blue dye in conscious rats. ET-1 and IRL 1620 (1 nmol kg-1) enhanced albumin extravasation by 109 and 82%, and 34 and 44% in the left ventricle and right atrium, respectively. ET-1 or IRL 1620-induced albumin extravasation was completely prevented by verapamil (1 mg kg-1) or nifedipine (200 micrograms kg-1) in these vascular beds. In contrast, hydralazine (0.2-0.3 mumol kg-1) failed to modify the effects of ET-1 or IRL 1620 on albumin extravasation. 6. These results show that verapamil and nifedipine are highly effective in protecting the myocardium against the pro-ischaemic and microvascular permeability enhancing effects of ET-1 and suggest that ETA and constrictor ETB (tentatively termed ETB2) receptors mediating these actions of ET-1 are coupled to calcium influx through dihydropyridine-sensitive calcium channels.

Full text

PDF
893

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. J., Barakeh J., Laskey R., Van Breemen C. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J. 1989 Oct;3(12):2389–2400. doi: 10.1096/fasebj.3.12.2477294. [DOI] [PubMed] [Google Scholar]
  2. Antman E., Muller J., Goldberg S., MacAlpin R., Rubenfire M., Tabatznik B., Liang C. S., Heupler F., Achuff S., Reichek N. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med. 1980 Jun 5;302(23):1269–1273. doi: 10.1056/NEJM198006053022301. [DOI] [PubMed] [Google Scholar]
  3. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  4. Bax W. A., Saxena P. R. The current endothelin receptor classification: time for reconsideration? Trends Pharmacol Sci. 1994 Oct;15(10):379–386. doi: 10.1016/0165-6147(94)90159-7. [DOI] [PubMed] [Google Scholar]
  5. Clozel M., Gray G. A., Breu V., Löffler B. M., Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992 Jul 31;186(2):867–873. doi: 10.1016/0006-291x(92)90826-7. [DOI] [PubMed] [Google Scholar]
  6. Curry F. E. Modulation of venular microvessel permeability by calcium influx into endothelial cells. FASEB J. 1992 Apr;6(7):2456–2466. doi: 10.1096/fasebj.6.7.1563597. [DOI] [PubMed] [Google Scholar]
  7. D'Orléans-Juste P., Claing A., Télémaque S., Maurice M. C., Yano M., Gratton J. P. Block of endothelin-1-induced release of thromboxane A2 from the guinea pig lung and nitric oxide from the rabbit kidney by a selective ETB receptor antagonist, BQ-788. Br J Pharmacol. 1994 Dec;113(4):1257–1262. doi: 10.1111/j.1476-5381.1994.tb17133.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davenport A. P., O'Reilly G., Kuc R. E. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995 Mar;114(6):1110–1116. doi: 10.1111/j.1476-5381.1995.tb13322.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Emori T., Hirata Y., Marumo F. Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Lett. 1990 Apr 24;263(2):261–264. doi: 10.1016/0014-5793(90)81388-5. [DOI] [PubMed] [Google Scholar]
  10. Entman M. L., Michael L., Rossen R. D., Dreyer W. J., Anderson D. C., Taylor A. A., Smith C. W. Inflammation in the course of early myocardial ischemia. FASEB J. 1991 Aug;5(11):2529–2537. doi: 10.1096/fasebj.5.11.1868978. [DOI] [PubMed] [Google Scholar]
  11. Filep J. G., Fournier A., Földes-Filep E. Effects of the ETA/ETB receptor antagonist, bosentan on endothelin-1-induced myocardial ischaemia and oedema in the rat. Br J Pharmacol. 1995 Sep;116(2):1745–1750. doi: 10.1111/j.1476-5381.1995.tb16657.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Filep J. G., Fournier A., Földes-Filep E. Endothelin-1-induced myocardial ischaemia and oedema in the rat: involvement of the ETA receptor, platelet-activating factor and thromboxane A2. Br J Pharmacol. 1994 Jul;112(3):963–971. doi: 10.1111/j.1476-5381.1994.tb13175.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Filep J. G., Földes-Filep E., Rousseau A., Fournier A., Sirois P., Yano M. Endothelin-1 enhances vascular permeability in the rat heart through the ETA receptor. Eur J Pharmacol. 1992 Aug 25;219(2):343–344. doi: 10.1016/0014-2999(92)90318-x. [DOI] [PubMed] [Google Scholar]
  14. Filep J., Fejes-Tóth G. Does vasopressin sustain blood pressure in conscious spontaneously hypertensive rats? Hypertension. 1986 Jun;8(6):514–519. doi: 10.1161/01.hyp.8.6.514. [DOI] [PubMed] [Google Scholar]
  15. Follath F. The role of calcium antagonists in the treatment of myocardial ischemia. Am Heart J. 1989 Nov;118(5 Pt 2):1093–1097. doi: 10.1016/0002-8703(89)90832-6. [DOI] [PubMed] [Google Scholar]
  16. Franco-Cereceda A. Endothelin- and neuropeptide Y-induced vasoconstriction of human epicardial coronary arteries in vitro. Br J Pharmacol. 1989 Jul;97(3):968–972. doi: 10.1111/j.1476-5381.1989.tb12038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gardner J. P., Tokudome G., Tomonari H., Maher E., Hollander D., Aviv A. Endothelin-induced calcium responses in human vascular smooth muscle cells. Am J Physiol. 1992 Jan;262(1 Pt 1):C148–C155. doi: 10.1152/ajpcell.1992.262.1.C148. [DOI] [PubMed] [Google Scholar]
  18. Goto K., Kasuya Y., Matsuki N., Takuwa Y., Kurihara H., Ishikawa T., Kimura S., Yanagisawa M., Masaki T. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc Natl Acad Sci U S A. 1989 May;86(10):3915–3918. doi: 10.1073/pnas.86.10.3915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Grega G. J., Adamski S. W., Dobbins D. E. Physiological and pharmacological evidence for the regulation of permeability. Fed Proc. 1986 Feb;45(2):96–100. [PubMed] [Google Scholar]
  20. Harada K., Miwa A., Kaneta S., Izawa T., Fukushima H., Ogawa N. Effects of KRN2391, nicorandil and diltiazem on the changes in the electrocardiogram caused by endothelin-1 in anaesthetized rats. Br J Pharmacol. 1993 Jul;109(3):679–684. doi: 10.1111/j.1476-5381.1993.tb13627.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Harrison V. J., Randriantsoa A., Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992 Mar;105(3):511–513. doi: 10.1111/j.1476-5381.1992.tb09009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hermán F., Magyar K., Chabrier P. E., Braquet P., Filep J. Prostacyclin mediates antiaggregatory and hypotensive actions of endothelin in anaesthetized beagle dogs. Br J Pharmacol. 1989 Sep;98(1):38–40. doi: 10.1111/j.1476-5381.1989.tb16859.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Highsmith R. F., Blackburn K., Schmidt D. J. Endothelin and calcium dynamics in vascular smooth muscle. Annu Rev Physiol. 1992;54:257–277. doi: 10.1146/annurev.ph.54.030192.001353. [DOI] [PubMed] [Google Scholar]
  24. Kim S., Morimoto S., Koh E., Miyashita Y., Ogihara T. Comparison of effects of a potassium channel opener BRL34915, a specific potassium ionophore valinomycin and calcium channel blockers on endothelin-induced vascular contraction. Biochem Biophys Res Commun. 1989 Nov 15;164(3):1003–1008. doi: 10.1016/0006-291x(89)91769-5. [DOI] [PubMed] [Google Scholar]
  25. Lawrence E., Siney L., Wilsoncroft P., Knock G. A., Terenghi G., Polak J. M., Brain S. D. Evidence for ETA and ETB receptors in rat skin and an investigation of their function in the cutaneous microvasculature. Br J Pharmacol. 1995 Jul;115(5):840–844. doi: 10.1111/j.1476-5381.1995.tb15009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lawson K., Barras M., Zazzi-Sudriez E., Martin D. J., Armstrong J. M., Hicks P. E. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers. Br J Pharmacol. 1992 Sep;107(1):58–65. doi: 10.1111/j.1476-5381.1992.tb14463.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lüscher T. F. Endothelin. Key to coronary vasospasm? Circulation. 1991 Feb;83(2):701–703. doi: 10.1161/01.cir.83.2.701. [DOI] [PubMed] [Google Scholar]
  28. Mayhan W. G., Joyner W. L. The effect of altering the external calcium concentration and a calcium channel blocker, verapamil, on microvascular leaky sites and dextran clearance in the hamster cheek pouch. Microvasc Res. 1984 Sep;28(2):159–179. doi: 10.1016/0026-2862(84)90015-3. [DOI] [PubMed] [Google Scholar]
  29. Mayhan W. G., Rubinstein I. Effects of endothelin receptor antagonists on bradykinin-induced increases in macromolecular efflux. Inflammation. 1994 Dec;18(6):633–644. doi: 10.1007/BF01535261. [DOI] [PubMed] [Google Scholar]
  30. Molenaar P., O'Reilly G., Sharkey A., Kuc R. E., Harding D. P., Plumpton C., Gresham G. A., Davenport A. P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993 Mar;72(3):526–538. doi: 10.1161/01.res.72.3.526. [DOI] [PubMed] [Google Scholar]
  31. Nayler W. G., Ou R. C., Gu X. H., Casley D. J. Effect of amlodipine pretreatment on ischaemia-reperfusion-induced increase in cardiac endothelin-1 binding site density. J Cardiovasc Pharmacol. 1992 Sep;20(3):416–420. doi: 10.1097/00005344-199209000-00011. [DOI] [PubMed] [Google Scholar]
  32. Nichols A. J., Koster P. F., Ohlstein E. H. The effect of diltiazem on the coronary haemodynamic and cardiac functional effects produced by intracoronary administration of endothelin-1 in the anaesthetized dog. Br J Pharmacol. 1990 Mar;99(3):597–601. doi: 10.1111/j.1476-5381.1990.tb12975.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ogawa Y., Nakao K., Arai H., Nakagawa O., Hosoda K., Suga S., Nakanishi S., Imura H. Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun. 1991 Jul 15;178(1):248–255. doi: 10.1016/0006-291x(91)91806-n. [DOI] [PubMed] [Google Scholar]
  34. Ogletree M. L. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc. 1987 Jan;46(1):133–138. [PubMed] [Google Scholar]
  35. Paul J., Bekker A. Y., Durán W. N. Calcium entry blockade prevents leakage of macromolecules induced by ischemia-reperfusion in skeletal muscle. Circ Res. 1990 Jun;66(6):1636–1642. doi: 10.1161/01.res.66.6.1636. [DOI] [PubMed] [Google Scholar]
  36. Prescott S. M., Zimmerman G. A., McIntyre T. M. Platelet-activating factor. J Biol Chem. 1990 Oct 15;265(29):17381–17384. [PubMed] [Google Scholar]
  37. Rubanyi G. M., Polokoff M. A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994 Sep;46(3):325–415. [PubMed] [Google Scholar]
  38. Sakata K., Ozaki H., Kwon S. C., Karaki H. Effects of endothelin on the mechanical activity and cytosolic calcium level of various types of smooth muscle. Br J Pharmacol. 1989 Oct;98(2):483–492. doi: 10.1111/j.1476-5381.1989.tb12621.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  40. Stanimirovic D. B., Yamamoto T., Uematsu S., Spatz M. Endothelin-1 receptor binding and cellular signal transduction in cultured human brain endothelial cells. J Neurochem. 1994 Feb;62(2):592–601. doi: 10.1046/j.1471-4159.1994.62020592.x. [DOI] [PubMed] [Google Scholar]
  41. Suzuki Y., Tanoi C., Shibuya M., Sugita K., Masuzawa-Ito K., Asano M. Different utilization of Ca2+ in the contractile action of endothelin-1 on cerebral, coronary and mesenteric arteries of the dog. Eur J Pharmacol. 1992 Sep 4;219(3):401–408. doi: 10.1016/0014-2999(92)90481-i. [DOI] [PubMed] [Google Scholar]
  42. Takai M., Umemura I., Yamasaki K., Watakabe T., Fujitani Y., Oda K., Urade Y., Inui T., Yamamura T., Okada T. A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor. Biochem Biophys Res Commun. 1992 Apr 30;184(2):953–959. doi: 10.1016/0006-291x(92)90683-c. [DOI] [PubMed] [Google Scholar]
  43. Takayanagi R., Kitazumi K., Takasaki C., Ohnaka K., Aimoto S., Tasaka K., Ohashi M., Nawata H. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett. 1991 Apr 22;282(1):103–106. doi: 10.1016/0014-5793(91)80454-b. [DOI] [PubMed] [Google Scholar]
  44. Teerlink J. R., Breu V., Sprecher U., Clozel M., Clozel J. P. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res. 1994 Jan;74(1):105–114. doi: 10.1161/01.res.74.1.105. [DOI] [PubMed] [Google Scholar]
  45. Turner N. C., Dollery C. T., Williams A. J. Endothelin-1-induced contractions of vascular and tracheal smooth muscle: effects of nicardipine and BRL 34915. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S180–S182. doi: 10.1097/00005344-198900135-00049. [DOI] [PubMed] [Google Scholar]
  46. Vigne P., Marsault R., Breittmayer J. P., Frelin C. Endothelin stimulates phosphatidylinositol hydrolysis and DNA synthesis in brain capillary endothelial cells. Biochem J. 1990 Mar 1;266(2):415–420. doi: 10.1042/bj2660415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Warner T. D., Allcock G. H., Mickley E. J., Corder R., Vane J. R. Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S117–S120. doi: 10.1097/00005344-199322008-00032. [DOI] [PubMed] [Google Scholar]
  48. Warner T. D., Schmidt H. H., Murad F. Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3. Am J Physiol. 1992 May;262(5 Pt 2):H1600–H1605. doi: 10.1152/ajpheart.1992.262.5.H1600. [DOI] [PubMed] [Google Scholar]
  49. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res. 1991 Aug;69(2):370–377. doi: 10.1161/01.res.69.2.370. [DOI] [PubMed] [Google Scholar]
  50. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T. D., Vane J. R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797–9800. doi: 10.1073/pnas.85.24.9797. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES